List of Excipients in Branded Drug VALACYCLOVIR HYDROCHLORIDE

Generic Drugs Containing VALACYCLOVIR HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	valacyclovir	0378-4275	FERROSOFERRIC OXIDE
Mylan Pharmaceuticals Inc	valacyclovir	0378-4275	HYPROMELLOSE 2910
Mylan Pharmaceuticals Inc	valacyclovir	0378-4275	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in VALACYCLOVIR HYDROCHLORIDE?

# Of NDCs	Excipient
2	ALUMINUM OXIDE
2	CARNAUBA WAX
78	CELLULOSE, MICROCRYSTALLINE

Valacyclovir Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Valacyclovir hydrochloride is a mature, off-patent oral antiviral used primarily for herpes zoster, genital herpes, and herpes labialis. The commercial opportunity is not a new chemical entity or biosimilar pathway. It is a formulation, manufacturing, supply-chain, and market-access opportunity centered on immediate-release tablets, pediatric liquids, orally disintegrating systems, and lower-cost global production.

Valacyclovir is the L-valyl ester prodrug of acyclovir. It improves oral acyclovir exposure through intestinal peptide transporter uptake and rapid conversion to acyclovir after absorption. The principal formulation challenge is balancing chemical stability, tablet manufacturability, dissolution, swallowing acceptability, and cost.[1]

What excipients are used in valacyclovir hydrochloride tablets?

Commercial valacyclovir hydrochloride tablets generally use conventional immediate-release excipients. Valtrex labeling identifies excipients including microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, polysorbate 80, titanium dioxide, and coating materials.[2]

Formulation function	Common excipients	Strategic purpose
Diluent and compression aid	Microcrystalline cellulose	Supports tablet hardness and direct compression
Disintegrant	Crospovidone	Promotes rapid tablet breakup
Binder	Povidone	Improves granule and tablet cohesion
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces tooling friction
Film coating	Hypromellose, polyethylene glycol, titanium dioxide	Protects the tablet and improves swallowability
Surfactant or wetting aid	Polysorbate 80	Can improve wetting and coating performance
Appearance and identification	Titanium dioxide, approved colorants	Supports product differentiation

The listed composition can differ between manufacturers, strengths, and markets. Generic applicants are not required to copy the Valtrex excipient system, provided the product satisfies quality, bioequivalence, and regulatory requirements.

What excipient properties matter most for valacyclovir hydrochloride?

The highest-value excipient decisions relate to moisture control, powder flow, tablet robustness, dissolution, and chemical stability.

Moisture management

Valacyclovir hydrochloride is vulnerable to degradation pathways associated with water and processing conditions. Excessive aqueous exposure during wet granulation can increase hydrolytic risk and create variability in assay or related substances. Direct compression or dry granulation can reduce water exposure, but these approaches require adequate flow and compactability.

Recommended development controls include:

• Low-moisture excipients where justified.
• Controlled relative humidity during dispensing and compression.
• Moisture-barrier packaging.
• Monitoring of related substances during accelerated stability testing.
• Avoidance of unnecessary aqueous coating exposure.
• Assessment of excipient peroxide content, particularly for polymeric excipients.

The commercial value of a moisture-control strategy is highest in hot and humid markets, where packaging and shelf-life failures can limit distribution.

Compression and tablet size

Valacyclovir tablets contain a relatively high drug load, particularly at the 1 g strength. Microcrystalline cellulose, low-substituted hydroxypropyl cellulose, or comparable compression aids can improve tablet integrity. Excessive use of diluent can increase tablet size and reduce patient acceptability.

A practical development target is a formulation that preserves:

• Adequate tensile strength.
• Low friability.
• Fast disintegration.
• Acceptable tablet weight.
• Consistent content uniformity.
• Low compression force sensitivity.

High tablet weight is a commercial disadvantage because valacyclovir is commonly administered in multi-day regimens and may require multiple tablets daily.

Lubrication control

Magnesium stearate is widely used, but over-lubrication can reduce tablet hardness and slow wetting or dissolution. Blending time, lubricant concentration, particle size, and shear exposure require control. A formulation that achieves low ejection force with limited magnesium stearate can reduce dissolution risk and improve process robustness.

Coating selection

Film coating improves appearance, swallowability, product identification, and handling. The coating should add limited weight and should not delay immediate release. Titanium dioxide and polymer coatings may create regulatory or customer-specific restrictions in some jurisdictions. Color-free or titanium-dioxide-free alternatives can support broader geographic distribution, but they may require new stability, identification, and process-control work.

What formulation strategies can differentiate valacyclovir products?

The strongest opportunities are dosage-form improvements rather than conventional tablets.

Pediatric oral liquid

Valacyclovir is used in pediatric patients for selected indications, but liquid administration creates stability, taste, dosing, and microbial-control challenges. A ready-to-use suspension or reconstitutable powder could compete where caregivers have difficulty administering large tablets.

A pediatric product would need to address:

• Strong bitterness and aftertaste.
• Dose uniformity after shaking.
• Sedimentation and redispersibility.
• Chemical stability throughout the in-use period.
• Preservative compatibility.
• Accurate dosing with oral syringes.
• Acceptable osmolality and viscosity.
• Low medication volume per dose.

Taste masking may use polymeric coating, ion-exchange resin complexation, lipid-based barriers, sweeteners, flavors, or multiparticulate systems. The formulation cannot materially delay release or impair conversion to acyclovir.

Orally disintegrating tablet

An orally disintegrating tablet could target patients with dysphagia, acute herpes labialis, or limited access to water. The principal formulation constraints are the high dose, bitter taste, tablet friability, and the need for rapid disintegration.

Potential technologies include:

• Crospovidone-based rapid disintegration.
• Porous tablets produced by specialized compression.
• Mannitol-based mouthfeel systems.
• Taste-masked granules.
• Sublingual or buccal delivery, although these are less likely to preserve the conventional valacyclovir value proposition.

An ODT would need a clear clinical or adherence advantage because patients can already take standard tablets with water.

Multiparticulate and sprinkle systems

Granules or mini-tablets in capsules, sachets, or sprinkle formulations could improve administration for patients who cannot swallow tablets. These systems introduce additional development requirements for:

• Taste masking.
• Dose uniformity.
• Segregation control.
• Moisture protection.
• Food-effect assessment.
• Packaging and dispensing compatibility.

Modified-release products

Modified-release valacyclovir is technically possible but commercially difficult. The drug is converted rapidly to acyclovir, and standard dosing already has broad clinical use. A sustained-release product would need to demonstrate a meaningful reduction in dosing frequency, improved adherence, or a clinical benefit that offsets formulation and regulatory costs.

What FDA regulatory pathway applies to valacyclovir hydrochloride?

Valacyclovir hydrochloride tablets are generally approved as abbreviated new drug applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product, together with adequate controls for identity, strength, quality, purity, and stability.[3]

For conventional immediate-release tablets, the regulatory burden is lower than for a new liquid, ODT, or modified-release product. A differentiated dosage form may require additional comparative dissolution, food-effect, stability, in-use, taste, device, or clinical data depending on the formulation and labeling claims.

Valacyclovir is a small-molecule drug. Biosimilar approval does not apply. The relevant competitive pathways are generic substitution, 505(b)(2) development for differentiated products, and non-U.S. national procedures.

What is the Orange Book and patent status of valacyclovir?

Valacyclovir hydrochloride is a mature product whose core U.S. compound and original product exclusivity have expired. Valtrex was marketed by GlaxoSmithKline and originated from the acyclovir prodrug research program associated with Burroughs Wellcome. Historic patents covered valacyclovir and related acyclovir prodrugs, but those rights no longer provide a current U.S. barrier to ordinary generic tablet entry.[4]

Exclusivity issue	Commercial assessment
Core compound patent	Expired
Original Valtrex product exclusivity	Expired
Conventional generic tablets	Established market
Current Orange Book barrier	No meaningful core-patent barrier for standard tablets
Formulation patents	Must be assessed product by product
Method-of-use patents	Potentially relevant only for specific new indications or dosing claims
Pediatric exclusivity	Historic exclusivity does not block current ordinary generic supply
Biosimilar pathway	Not applicable

A later patent could still protect a particular formulation, manufacturing process, delivery system, or new method of use. Such rights would not automatically block a conventional valacyclovir hydrochloride tablet that does not practice the claimed invention.

When does valacyclovir lose exclusivity and what are the generic entry risks?

The principal loss of exclusivity occurred years ago, and multiple generic suppliers now compete in the U.S. and international markets. The risk profile is therefore different from a late-life branded medicine approaching patent expiry.

Generic entry risks include:

1. Price compression. Standard tablets are vulnerable to multi-source competition and pharmacy purchasing pressure.
2. API concentration. Dependence on a limited group of qualified active pharmaceutical ingredient suppliers can create shortages or cost volatility.
3. Quality-event exposure. A single supplier recall can affect downstream products if manufacturing sources are concentrated.
4. Dissolution variability. Differences in particle size, compression, lubrication, and coating can affect release performance.
5. Regulatory fragmentation. Pediatric liquids, ODTs, and modified-release products may require different approval packages across jurisdictions.
6. Packaging cost. Moisture-barrier packaging can reduce margins in low-price markets.

Paragraph IV challenges were commercially relevant during the original generic-entry period. They are no longer the central market-access issue for standard valacyclovir tablets because the product is already broadly genericized. Any future Paragraph IV filing would more likely target a later patent covering a specific formulation or use, not the expired core product.

What commercial opportunities exist for valacyclovir excipients and formulations?

Contract manufacturing and private-label supply

The most immediate opportunity is reliable, low-cost production of 500 mg and 1 g immediate-release tablets. Buyers value:

• Multiple qualified API sources.
• Low reject and deviation rates.
• Stable dissolution across scale.
• Flexible blister and bottle packaging.
• Registration support in multiple countries.
• Supply continuity during demand spikes.

Pediatric products

A stable, palatable pediatric suspension has greater differentiation potential than another standard tablet. Hospitals, specialty pharmacies, and public-health procurement programs may value a dosage form that reduces administration errors.

Global packaging and stability systems

Moisture-resistant blister systems, desiccant-enabled bottles, and heat-stable packaging can create a practical advantage in tropical markets. The opportunity is operational rather than patent-based and depends on total delivered cost.

Low-excipient and allergen-sensitive products

Products excluding selected dyes, lactose, titanium dioxide, or animal-derived materials may gain access to institutional or jurisdiction-specific tenders. The commercial value depends on documented demand and does not necessarily support a premium price.

Combination and adherence products

A fixed-dose combination with another antiviral or symptom-management agent would face substantial regulatory, clinical, and market hurdles. The combination would need a clear adherence or clinical rationale. Co-packaged regimens are more feasible than new fixed-dose combinations but may provide limited patent protection.

How does valacyclovir compare with acyclovir and famciclovir?

Attribute	Valacyclovir	Acyclovir	Famciclovir
Active form after conversion	Acyclovir	Acyclovir	Penciclovir
Prodrug	Yes	No	Yes
Oral exposure	Higher than acyclovir	Lower	Higher than acyclovir
Typical commercial form	Immediate-release tablet	Tablet, suspension, topical products	Immediate-release tablet
Excipient opportunity	Pediatric liquid, ODT, packaging	Broader liquid and topical differentiation	Tablet and adherence positioning
Patent barrier	Expired core rights	Expired core rights	Expired core rights
Competitive pressure	High generic competition	High generic competition	Smaller but established market

Valacyclovir’s principal commercial advantage over acyclovir is dosing convenience derived from improved oral exposure. Its principal disadvantage is that the tablet must deliver a high dose while maintaining acceptable size, hardness, and dissolution.

What patent litigation and settlement issues affect valacyclovir?

Current commercial risk is primarily formulation-specific rather than centered on the original valacyclovir molecule. Historic generic litigation surrounding Valtrex and related products has largely run its course with the expiration of relevant rights and the emergence of multiple generic suppliers.

Future disputes could involve:

• A pediatric suspension patent.
• Taste-masking technology.
• An ODT manufacturing process.
• A modified-release system.
• A new indication or dosing schedule.
• Trade secrets involving API crystallization or impurity control.
• Supplier qualification and confidential manufacturing know-how.

A settlement involving a later formulation patent could restrict only the accused product or claimed use. It would not necessarily restore exclusivity to the conventional tablet market.

How strong is the valacyclovir patent estate?

The core patent estate is commercially weak because the foundational rights have expired. The remaining defensible positions are narrow and technology-dependent.

Patent category	Strength for a new entrant
Core valacyclovir composition	Low
Conventional tablet formulation	Low
Specific excipient ratio	Low to moderate, if technically supported
Pediatric taste-masked suspension	Moderate
ODT or multiparticulate delivery	Moderate
Novel manufacturing process	Moderate
New indication	Potentially moderate, subject to clinical evidence
Trade secrets and process know-how	Potentially strong but non-patent based

A new product should not rely on routine excipient selection for meaningful exclusivity. Commercial protection is more credible when the formulation solves a measurable problem, such as stability in suspension, dose uniformity, taste masking, or reduced dosing burden.

Key Takeaways

• Valacyclovir hydrochloride is an established generic small-molecule antiviral with expired core exclusivity.
• Conventional tablets use standard excipients such as microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, and film-coating polymers.
• Moisture control, lubrication, dissolution, tablet size, and high drug load are the main formulation priorities.
• Pediatric liquids, ODTs, multiparticulates, and robust tropical-market packaging offer the clearest differentiation opportunities.
• Biosimilar risk is irrelevant because valacyclovir is not a biologic.
• Current U.S. competition is driven by generic pricing, API reliability, manufacturing scale, and regulatory execution.
• Patent value is limited for routine tablets and stronger only for genuinely differentiated delivery systems or manufacturing processes.

FAQs

Can valacyclovir hydrochloride be formulated as a pediatric suspension?

Yes. A pediatric suspension is technically feasible but requires control of taste, chemical stability, sedimentation, redispersibility, microbial quality, and dose uniformity.

Which excipient is most important for rapid valacyclovir tablet disintegration?

Crospovidone is a common high-performance disintegrant, but its effectiveness depends on particle size, concentration, compression force, and the complete formulation.

Does valacyclovir require a moisture-barrier package?

A moisture-barrier package is commercially prudent because moisture can affect chemical stability and tablet performance, particularly during long storage in hot and humid climates.

Is a valacyclovir orally disintegrating tablet patentable?

Potentially, but patentability depends on a novel and non-obvious formulation or manufacturing process. Routine substitution of common disintegrants or sweeteners is unlikely to provide strong protection.

Is valacyclovir hydrochloride subject to biosimilar competition?

No. Valacyclovir hydrochloride is a synthetic small molecule. Competition occurs through generic drug applications and, for differentiated products, potentially through 505(b)(2) development.

References

1. U.S. Food and Drug Administration. (2008). Valtrex (valacyclovir hydrochloride) prescribing information. GlaxoSmithKline.

2. U.S. Food and Drug Administration. (2008). Valtrex prescribing information: Description and inactive ingredients. GlaxoSmithKline.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. U.S. Patent and Trademark Office. (1989). U.S. Patent No. 4,957,924: Acyclovir prodrugs. United States Patent and Trademark Office.